Investigations have shown that SPARC promotes pathological reactions in non-small-cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis by encouraging microvascular remodeling and overproduction of ECM proteins (Wong and Sukkar, 2017). Here, SPARC is linked to pulmonary fibrosis.